ASML vs KLA: buybacks, guidance and one sale

ASML and KLA are both riding the same capex wave, but only one owns the choke point

ASML and KLA are both tied to the same AI spending cycle, but they do not occupy the same place in the chain. KLA sells the tools that help fabs measure and control the process. ASML sells the lithography systems that make the most advanced chips possible in the first place. That distinction matters when the market starts arguing about whether the AI buildout is broadening or merely getting more expensive.

ASML closed at $1,662.85 on Nasdaq on October 28, 2026, up $27.28, or 1.67%, after a rough patch that included a roughly 7% drop on October 22. On Euronext Amsterdam it finished at €1,489.60, up 1.33%. The stock is still trading near the top of a 52-week range that runs from $946.11 to $1,999.96, which tells you the market has already assigned a lot of value to the story. KLA, by contrast, has been a steadier way to express the same semiconductor capex theme, with first-quarter revenue of $4.14 billion. ASML is the more concentrated bet. It also has the more obvious choke point.

The buyback ledger says one thing, the chart says another

ASML’s latest company-specific disclosure came on October 26, when it reported repurchases of 343,310 shares for EUR 499.27 million during the week of October 19 to 23, under the existing program announced in January 2026. That is not a token gesture. It is a large, deliberate bid under the stock, and it arrived while the market was still digesting a volatile stretch in semis and broader technology.

The timing matters because the company also just put up a strong quarter. On October 14, ASML reported third-quarter 2026 net sales of EUR 11.7 billion, net profit of EUR 5.0 billion, and a gross margin of 57.5%. Management then guided fourth-quarter 2026 net sales to EUR 14.2 billion to EUR 15.2 billion with gross margin around 57%, and raised the full-year 2026 outlook to EUR 44 billion to EUR 45 billion in sales at a gross margin around 56%. That is the kind of update that keeps a premium multiple alive. It also explains why the stock can sell off on a bad tape and still recover quickly. The business is still throwing off enough cash to fund repurchases at scale.

Capacity, not demand, is the ceiling ASML keeps talking about

The company’s own message is not that demand has softened. It is that supply is the constraint. ASML has said planned supply of advanced systems will not fully meet customer demand through 2027 to 2028, and it is examining further capacity expansions beyond the previously communicated 30% increase for 2027 and an additional 30% aspiration for 2028. That is a very specific kind of problem. It is the sort of problem a monopoly-like supplier gets to have when customers cannot easily go elsewhere.

Management has also said order visibility stretches into 2029 to 2030 according to recent commentary. That is a long runway, but it is not a blank check. Tools still have to ship. Customers still have to fund the capex. And the market still has to decide whether the next leg of AI spending is enough to justify the price already embedded in the stock. The answer is not obvious, which is why the shares can trade like a momentum name even when the underlying business looks more like an infrastructure bottleneck.

KLA sits in the same capital spending cycle, but the comparison stops there. KLA’s revenue print shows healthy demand, yet ASML’s position is more singular. If you want exposure to the semiconductor buildout, KLA gives you a broad equipment read. If you want the one company that can slow the pace of leading-edge logic and memory production, ASML is the name. That is why the market keeps treating every capacity update as a macro event.

The insider record is not loud, and that is the point

On the insider side, the recent activity is modest and mixed. CFO Roger Dassen sold 3,000 shares on October 16 at approximately €1,479.80 per share, according to the filing record. Supervisory board member Birgit Conix made small open-market purchases in mid-October. There is no evidence here of a broad insider stampede in either direction. No dramatic cluster. No obvious panic. No obvious all-in bet either.

That matters because ASML is not a small, opaque industrial where a single director trade can carry a lot of interpretive weight. This is a large, heavily followed semiconductor franchise with a stock that already trades on a dense mix of order visibility, margin power, and strategic scarcity. A lone executive sale does not rewrite that. A small board purchase does not either. You read the filing against the business, not the other way around.

Insiders Trades data shows a historical T+90 cohort return of +2.6% for the relevant role and size bucket. That is historical cohort data, not a forecast for ASML and not a promise that this trade will do anything similar. It is a useful reminder that the bucket can lean positive over time, but the dispersion is the real story. Some filings matter because they arrive with a business inflection. Some do not. This one sits in the middle, which is exactly where a mature megacap insider record often lives.

Samsung, SK Hynix and the rest of the chain keep validating the demand story

The broader semiconductor backdrop still favors ASML’s core thesis. Samsung Electronics reported operating profit of KRW 107.4 trillion, about $80 billion, on revenue of KRW 195.3 trillion, while SK Hynix and Samsung both pointed to AI-related products and high-bandwidth memory as major drivers of the current cycle. The message from the memory side is simple enough. AI demand is still outrunning supply, and the industry is still trying to catch up.

That is useful context for ASML because the company does not need every customer to be perfect. It needs the leading-edge nodes to keep advancing and the capex budgets to keep flowing. When Samsung and SK Hynix are still talking about shortages and record profits, the lithography bottleneck remains relevant. When KLA posts strong revenue, it reinforces the idea that equipment spending is still alive. ASML sits above both of those reads. It is the toll booth on the road to the most advanced chips.

The market knows this, which is why the stock has been able to absorb volatility and still hold a premium posture. But the same setup also makes the shares sensitive to any hint that the capex cycle is peaking, or that customers are stretching out timing rather than accelerating it. The company’s own guidance suggests the opposite. The market, as usual, is less patient than management.

Valuation is the argument, execution is the answer

This is where the comparison with KLA gets useful. KLA has been rewarded for execution and for exposure to a healthy equipment cycle. ASML gets rewarded for execution plus scarcity. That extra layer cuts both ways. Scarcity supports the multiple when demand is strong. It also leaves less room for disappointment when the stock has already run hard.

Analyst commentary has stayed mostly constructive. Citigroup reaffirmed a buy rating on October 15, Wall Street Zen upgraded to buy on October 17, Weiss Ratings moved to buy on October 16, and JPMorgan lowered its price target to $2,350 from $2,400 while keeping an overweight rating. That is not a bearish wall of worry. It is a market trying to decide how much of the future is already in the price. Antipodes Global Fund also highlighted a new position in ASML in its Q3 2026 letter, calling the company indispensable as the sole supplier of leading-edge EUV systems and pointing to multi-year order visibility.

The valuation debate is therefore not about whether ASML matters. It clearly does. The debate is whether the current price already discounts too much of that importance. The stock’s 52-week range says the market has been willing to pay up aggressively. The recent pullback says it is not willing to do so without pauses. KLA offers a cleaner, less dramatic way to own the equipment cycle. ASML offers the scarcer asset. You pay for that privilege.

What to watch while the stock keeps arguing with itself

The next few checkpoints are straightforward. First, watch whether the buyback pace stays active after the October 19 to 23 repurchase window. A company that keeps leaning on its own stock is telling you it still sees value, even if the market is busy debating the multiple. Second, watch whether management keeps talking about capacity expansion beyond the already stated 30% increase for 2027 and the additional 30% aspiration for 2028. If that language gets firmer, the supply story gets stronger. If it softens, the market will notice quickly.

Third, watch the customer side. Samsung and SK Hynix are still validating the AI demand narrative, and KLA’s revenue shows the equipment cycle has not rolled over. But ASML’s stock will not trade on those names alone. It will trade on whether the company can keep converting order visibility into shipped systems and margin discipline. That is the real comparison with KLA. KLA can do well in a healthy cycle. ASML needs the cycle, and it needs the bottleneck to stay intact.

The insider record does not change that framework. Dassen’s sale and Conix’s small purchases are background noise unless they start to cluster or scale. For now, the more important facts are the raised 2026 outlook, the EUR 499.27 million buyback week, and the company’s own warning that demand still outruns supply. Those are the numbers that matter when you are deciding whether ASML is still the better way to own the AI equipment trade than a peer like KLA.

This is not investment advice.